Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Gerald Hsu

Lymphoma · UCSF

View

Dr. Chadi Nabhan

Lymphoma · Ryght AI / USC

View

Dr. Mark Roschewski

Lymphoma · MSK

View

Dr. Jonathan Friedberg

Lymphoma · URMC

View

Dr. Matthew Matasar

Lymphoma · Rutgers Cancer Institute

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    JSDr. Jose Sandoval-sus

    Dr. Jose Sandoval-sus

    Hematology & Oncology · Lymphoma
    Moffitt Cancer Center
    joses

    Research

    Should CAR-T cell therapy be considered a standard of care for patients with refractory diffuse large B-cell lymphoma in second line treatment?

    2025

    Via Expert opinion on biological therapy

    Research

    Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study

    2025

    Via Bone marrow transplantation

    Research

    Final results of a multicentre pilot study evaluating brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide and prednisone (BV-CHEP) for the treatment of aggressive adult T-cell leukaemia/lymphoma

    2025

    Via British journal of haematology

    Research

    Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study

    2025

    Via Research square

    Research

    Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial

    2025

    Via The Lancet. Haematology

    Research

    Bruton's Tyrosine Kinase Inhibitors: Recent Updates

    2024

    Via International journal of molecular sciences

    Research

    Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis

    2024

    Via Clinical lymphoma, myeloma & leukemia

    Research

    High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series

    2024

    Via Blood advances

    Research

    Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial

    2024

    Via The Lancet. Haematology

    Research

    Outcomes of follicular lymphoma with leukemic phase in the modern era: results from a large multicenter study

    2024

    Via Blood neoplasia

    Research

    High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study

    2023

    Via Blood advances

    Research

    Poor Outcome of Adult T-Cell Leukemia/Lymphoma with Current Available Therapy: An Experience of Two Centers

    2023

    Via Oncology research and treatment

    Research

    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy

    2023

    Via Bone marrow transplantation

    Research

    An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

    2022

    Via Blood advances

    Research

    Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease

    2022

    Via Current oncology reports